Evolent Health Inc · Q1 2022 earnings

Briefing

Evolent Health reported strong organic growth and margin expansion, announcing two operating partner additions and one client expansion.

Evolent Health's Q1 2022 revenue reached $297.1 million, a 38.1% increase year-over-year. The company reported a net loss of $5.4 million, but achieved an adjusted EBITDA of $24.3 million. They also added two operating partnerships and announced a client expansion for 2023.

• GAAP revenue increased by 38.1% to $297.1 million compared to Q1 2021.
• Net loss attributable to common shareholders was $5.4 million, resulting in a net loss margin of (1.8)%.
• Adjusted EBITDA reached $24.3 million, with an adjusted EBITDA margin of 8.2%.
• Total Lives on Platform reached 20.3 million, including 2.1 million Evolent Health Services Lives and 18.2 million Clinical Solutions Lives.

Headline financials

Revenue & EPS history

For Q2 2022, Evolent anticipates revenue between $290.0 million and $305.0 million, and adjusted EBITDA between $18.0 million and $23.0 million. For the full year 2022, revenue is expected to be between $1.16 billion and $1.21 billion, and adjusted EBITDA between $85.0 million and $95.0 million.